Health-care companies fell as traders rotated out of high-risk sectors such as biotechnology.
Walgreen Boots Alliance rallied after it named Cigna official Tim Wentworth as chief executive, spurring hopes for a revival of the drug-store chain's fortunes after difficulty integrating British firm Boots.
U.S. health officials are banning the sale of Vuse Alto menthol e-cigarettes, which have surpassed Juul as the top-selling vaping products in the country amid a regulatory crackdown.
The relentless advance in makers of obesity drugs continued, as Novo Nordisk shares rose for the ninth time in 10 sessions.
Shares of oncology drug maker Illumina slid after the European Union ordered the firm to unwind its $7.1 billion acquisition of cancer-test developer Grail.
RVL Pharmaceuticals said several of its units were filing for bankruptcy in a prepackaged deal with lender Athyrium Capital and other key stakeholders.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
10-12-23 1802ET
